| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016PLoSO..1152422M |
| P356 | DOI | 10.1371/JOURNAL.PONE.0152422 |
| P932 | PMC publication ID | 4816515 |
| P698 | PubMed publication ID | 27032101 |
| P5875 | ResearchGate publication ID | 299538759 |
| P2093 | author name string | Erick Suárez | |
| Jaime Matta | |||
| Luisa Morales | |||
| Miguel Echenique | |||
| Julie Dutil | |||
| Carmen Ortiz | |||
| Damian Adams | |||
| Patricia Casbas | |||
| Wanda Vargas | |||
| P2860 | cites work | Deficient nucleotide excision repair capacity enhances human prostate cancer risk | Q23914668 |
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer | Q24338724 | ||
| Targeting abnormal DNA repair in therapy-resistant breast cancers | Q24605455 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes | Q27009257 | ||
| Interaction of estrogen receptor alpha with 3-methyladenine DNA glycosylase modulates transcription and DNA repair | Q28242358 | ||
| Breast Cancer and DNA Repair Capacity: Association With Use of Multivitamin and Calcium Supplements | Q33575548 | ||
| Estrogen signaling and the DNA damage response in hormone dependent breast cancers | Q33646842 | ||
| Interaction of the double-strand break repair kinase DNA-PK and estrogen receptor-alpha | Q33818511 | ||
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q33862786 | ||
| Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer | Q33968076 | ||
| Estrogens, BRCA1, and breast cancer | Q34052223 | ||
| Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention | Q34103963 | ||
| Deconstructing the molecular portraits of breast cancer | Q34154147 | ||
| Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. | Q34158588 | ||
| DNA methylation: an alternative pathway to cancer | Q34290123 | ||
| Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer | Q34308770 | ||
| Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer | Q34410934 | ||
| The association of DNA Repair with breast cancer risk in women. A comparative observational study | Q34454257 | ||
| A clinicopathological study of early-stage synchronous bilateral breast cancer: a retrospective evaluation and prospective validation of potential risk factors | Q35149371 | ||
| Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy | Q35214307 | ||
| A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis | Q35683556 | ||
| Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes | Q36032594 | ||
| DNA repair and aging in basal cell carcinoma: a molecular epidemiology study | Q36118189 | ||
| A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma. | Q53336069 | ||
| American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. | Q55154696 | ||
| Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer | Q70651028 | ||
| Reduced DNA repair capacity in head and neck cancer patients | Q74705723 | ||
| A modified host-cell reactivation assay to quantify DNA repair capacity in cryopreserved peripheral lymphocytes | Q84046289 | ||
| Estrogen and cancer | Q87416260 | ||
| Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers? | Q36205009 | ||
| The genomic landscape of breast cancer as a therapeutic roadmap | Q36558069 | ||
| Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. | Q36589865 | ||
| Mechanisms of Endocrine Resistance in Breast Cancer | Q36851417 | ||
| ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer | Q37013898 | ||
| DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. | Q37247163 | ||
| Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair | Q37262148 | ||
| Apurinic/apyrimidinic endonuclease 1 alters estrogen receptor activity and estrogen-responsive gene expression | Q37332450 | ||
| Factors associated with breast cancer in Puerto Rican women | Q37414400 | ||
| Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance | Q37472631 | ||
| Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). | Q37565213 | ||
| Biological determinants of endocrine resistance in breast cancer | Q37585095 | ||
| Multidrug-resistant breast cancer: current perspectives | Q37593383 | ||
| DNA repair in cancer: emerging targets for personalized therapy. | Q37600799 | ||
| Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. | Q37686055 | ||
| Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance | Q37962586 | ||
| Epigenetics of estrogen receptor-negative primary breast cancer | Q38012175 | ||
| Chromatin landscape and endocrine response in breast cancer. | Q38067765 | ||
| Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition | Q38068586 | ||
| The role of microRNA in resistance to breast cancer therapy | Q38231981 | ||
| Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. | Q38245797 | ||
| Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol | Q39378402 | ||
| Paracrine-acting adiponectin promotes mammary epithelial differentiation and synergizes with genistein to enhance transcriptional response to estrogen receptor β signaling | Q39516453 | ||
| Is the prevalence of ER-negative breast cancer in the US higher among Africa-born than US-born black women? | Q39564960 | ||
| Impact of breast cancer resistance protein on cancer treatment outcomes | Q39769042 | ||
| Development and field-test validation of an assay for DNA repair in circulating human lymphocytes | Q41138849 | ||
| Reduced DNA repair capacity in lung cancer patients | Q41167956 | ||
| Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy | Q42144454 | ||
| DNA repair and nonmelanoma skin cancer in Puerto Rican populations | Q42447299 | ||
| Factors that influence the DNA repair capacity of normal and skin cancer-affected individuals. | Q42473941 | ||
| Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis | Q42936074 | ||
| Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4. | Q42938792 | ||
| BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer | Q43497738 | ||
| Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer | Q45009837 | ||
| Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. | Q45925101 | ||
| Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers | Q46372134 | ||
| Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers | Q46782748 | ||
| DNA repair and breast carcinoma susceptibility in women | Q47887299 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0152422 | |
| P577 | publication date | 2016-03-31 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Estrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer | |
| P478 | volume | 11 |
| Q92376374 | 5',8-Cyclopurine Lesions in DNA Damage: Chemical, Analytical, Biological, and Diagnostic Significance |
| Q89315877 | A Preliminary Study: Human Fibroid Stro-1+/CD44+ Stem Cells Isolated From Uterine Fibroids Demonstrate Decreased DNA Repair and Genomic Integrity Compared to Adjacent Myometrial Stro-1+/CD44+ Cells |
| Q58796166 | A combined approach with gene-wise normalization improves the analysis of RNA-seq data in human breast cancer subtypes |
| Q98288891 | Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations |
| Q49842996 | Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol |
| Q37050612 | High DRC Levels Are Associated with Let-7b Overexpression in Women with Breast Cancer |
| Q38809426 | Purine 5',8-cyclo-2'-deoxynucleoside lesions: formation by radical stress and repair in human breast epithelial cancer cells. |
| Q40123917 | Variability in DNA Repair Capacity Levels among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair |
Search more.